Wedbush Maintains Outperform on Viridian Therapeutics, Raises Price Target to $43
Wedbush analyst Laura Chico maintains Viridian Therapeutics (NASDAQ: VRDN ) with a Outperform and raises the price target from $32 to $43.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.